F901318 + caspofungin

F901318 + caspofungin is a **combination antifungal therapy** involving F901318 (also known as olorofim), a first-in-class orotomide antifungal that inhibits **dihydroorotate dehydrogenase** (DHODH) in fungal pyrimidine biosynthesis, and caspofungin, an echinocandin antifungal that inhibits **β-(1,3)-glucan synthase** required for fungal cell wall synthesis[1][2][3][5][6]. The combination is being explored to target invasive fungal infections, especially those resistant to other treatments. F901318 exhibits potent fungistatic and fungicidal activity (particularly with prolonged or high exposure) against *Aspergillus* species and other filamentous fungi, while caspofungin disrupts cell wall integrity, leading to fungal cell death[1][2][3][5][6]. This combination exploits two distinct mechanisms to achieve synergistic antifungal efficacy.

Other names

olorofim + caspofungin